These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 19801202)

  • 1. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
    Mook S; Schmidt MK; Rutgers EJ; van de Velde AO; Visser O; Rutgers SM; Armstrong N; van't Veer LJ; Ravdin PM
    Lancet Oncol; 2009 Nov; 10(11):1070-6. PubMed ID: 19801202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant! When the new world meets the old world.
    Huober J; Thürlimann B
    Lancet Oncol; 2009 Nov; 10(11):1028-9. PubMed ID: 19880058
    [No Abstract]   [Full Text] [Related]  

  • 3. A nomogram to predict individual prognosis in node-negative breast carcinoma.
    Mazouni C; Spyratos F; Romain S; Fina F; Bonnier P; Ouafik LH; Martin PM
    Eur J Cancer; 2012 Nov; 48(16):2954-61. PubMed ID: 22658808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
    Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
    Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population.
    van Maaren MC; van Steenbeek CD; Pharoah PDP; Witteveen A; Sonke GS; Strobbe LJA; Poortmans PMP; Siesling S
    Eur J Cancer; 2017 Nov; 86():364-372. PubMed ID: 29100191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
    Chia S; Norris B; Speers C; Cheang M; Gilks B; Gown AM; Huntsman D; Olivotto IA; Nielsen TO; Gelmon K
    J Clin Oncol; 2008 Dec; 26(35):5697-704. PubMed ID: 19001334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study.
    de Glas NA; van de Water W; Engelhardt EG; Bastiaannet E; de Craen AJ; Kroep JR; Putter H; Stiggelbout AM; Weijl NI; van de Velde CJ; Portielje JE; Liefers GJ
    Lancet Oncol; 2014 Jun; 15(7):722-9. PubMed ID: 24836274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
    Olivotto IA; Bajdik CD; Ravdin PM; Speers CH; Coldman AJ; Norris BD; Davis GJ; Chia SK; Gelmon KA
    J Clin Oncol; 2005 Apr; 23(12):2716-25. PubMed ID: 15837986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
    Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
    Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
    Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients.
    Bastiaannet E; Liefers GJ; de Craen AJ; Kuppen PJ; van de Water W; Portielje JE; van der Geest LG; Janssen-Heijnen ML; Dekkers OM; van de Velde CJ; Westendorp RG
    Breast Cancer Res Treat; 2010 Dec; 124(3):801-7. PubMed ID: 20428937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
    Montagna E; Bagnardi V; Rotmensz N; Viale G; Pruneri G; Veronesi P; Cancello G; Balduzzi A; Dellapasqua S; Cardillo A; Luini A; Zurrida S; Gentilini O; Mastropasqua MG; Bottiglieri L; Iorfida M; Goldhirsch A; Colleoni M
    Breast Cancer Res Treat; 2010 Dec; 124(3):689-99. PubMed ID: 20625816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
    Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
    Györffy B; Lanczky A; Eklund AC; Denkert C; Budczies J; Li Q; Szallasi Z
    Breast Cancer Res Treat; 2010 Oct; 123(3):725-31. PubMed ID: 20020197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for longer disease free survival and overall survival after surgical resection of isolated liver metastasis from breast cancer.
    Zegarac M; Nikolic S; Gavrilovic D; Jevric M; Kolarevic D; Nikolic-Tomasevic Z; Kocic M; Djurisic I; Inic Z; Ilic V; Santrac N
    J BUON; 2013; 18(4):859-65. PubMed ID: 24344009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.